A guidance pathway for the selection of novel anticoagulants in the treatment of atrial fibrillation

Critical Pathways in Cardiology

Volumn 11, Issue 2, 2012, Pages 55-61

  Wisler, James W ^a   Becker, Richard C ^b  

^a DUKE UNIVERSITY HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

atrial fibrillation; direct thrombin inhibitors; factor Xa inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; APIXABAN; CLOPIDOGREL; DABIGATRAN ETEXILATE; DILTIAZEM; ENOXAPARIN; KETOCONAZOLE; PLACEBO; QUINIDINE; RIFAMPICIN; RIVAROXABAN; VERAPAMIL; WARFARIN;

ALGORITHM; ANTICOAGULANT THERAPY; ANTICOAGULATION; AREA UNDER THE CURVE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; STROKE; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; FACTOR XA; HUMANS; STROKE;

EID: 84861448442     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0b013e31825298ef     Document Type: Review

References (48)

1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004;110:1042-1046. (Pubitemid 39319000)
2. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949-953.
3. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol; 2011; 57: e101-e198.
4. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492-501. (Pubitemid 29482392)
5. Baker WL, Cios DA, Sander SD, Coleman CI. Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15:244-252.
6. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med. 2010;123:638-645.e4.
7. Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41-57.
8. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699-708.
9. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009;48:1-22.
10. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386-399. (Pubitemid 351185753)
11. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
12. Wann LS, Curtis AB, January CT, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123: 104-123.
13. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-817.
14. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
15. Davis EM, Packard KA, Knezevich JT, Campbell JA. New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome. Pharmacotherapy. 2011;31:975-1016.
16. Weinz C, Radtke M, Schmeer K, Kern A, Pleiss U. In vitro metabolism of BAY 59-7939-an oral, direct factor Xa inhibitor. Drug Metab Rev. 2004;36:98 (abstract 195).
17. Weinz C, Schwarz T, Pleiss U, et al. Metabolism and distribution of [C-14]BAY 59-7939-an oral, direct factor Xa inhibitor-in rat, dog and human. Drug Metab Rev. 2004;36:98 (abstract 196).
18. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
19. Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011;32:2387-2394.
20. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.
21. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-1100.
22. Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15:e22-e33.
23. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 1987;147:1561-1564. (Pubitemid 17138836)
24. Fang MC, Go AS, Hylek EM, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54:1231-1236. (Pubitemid 44166528)
25. Fang MC, Chang Y, Hylek EM, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141:745-752.
26. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007;115:2689-2696. (Pubitemid 46842784)
27. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363-2372.
28. Janssen Pharmaceuticals I. Xarelto (rivaroxaban) Tablets: Prescribing Information. Titusville, NJ; 2011 [updated 2011]. Available at: http://www.xareltohcp.com/sites/default/files/pdf/xarelto-0.pdf - zoom=100. Accessed December 27, 2011.
29. Janssen Pharmaceuticals I. FDA Draft Briefing Document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC): Xarelto (rivaroxaban) tablets. Titusville, NJ; 2011 [updated 2011]. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm270796.pdf. Accessed December 27, 2011.
30. Grand'Maison A, Charest AF, Geerts WH. Anticoagulant use in patients with chronic renal impairment. Am J Cardiovasc Drugs. 2005;5:291-305. (Pubitemid 41306468)
31. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis. 2010;56:823-831.
32. Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb Haemost. 2011;9:2168-2175.
33. Eikelboom JW, O'Donnell M, Yusuf S, , et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment. Am Heart J. 2010;159:348-353e1.
34. Lopes RD, Alexander JH, Al-Khatib SM, et al. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331-339.
35. Altman R, Vidal HO. Battle of oral anticoagulants in the field of atrial fibrillation scrutinized from a clinical practice (the real world) perspective. Thromb J. 2011;9:12.
36. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124:1573-1579.
37. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165:1095-1106. (Pubitemid 40720733)
38. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S-198S. (Pubitemid 351892967)
39. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31:326-343.
40. European Medicines Agency E. European public assessment report: Pradaxa [online]. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/EPAR-Summary-for-the-public/human/000829/WC500041060.pdf. Accessed December 27, 2011.
41. Boehringer Ingelheim Pharmaceuticals I. Pradaxa [prescribing information]. Ridgefield, CT; 2011 [updated 2011]. Available at: http://bidocs.boehringer- ingelheim.com/BIWebAccess/ViewServlet.ser?docBase= renetntfolderPath=/Prescribing Information/PIs/Pradaxa/Pradaxa.pdf. Accessed December 27, 2011.
42. Janssen Pharmaceuticals I. Xarelto (rivaroxaban 10 mg tablets): Product Monograph [online]; 2011 [updated 2011]. Available at: http://www.bayer.ca/ files/XARELTO-PM-ENG-14SEP2011-142438.pdf. Accessed December 27, 2011.
43. Bristol-Myers Squbb I, Pfizer I. Eliquis: Summary of Product Information. New York, NY, Princeton, NJ; 2011 [updated 2011]. Available at: http://www.eliquis.com/PDF/ELIQUIS %C2%AE (apixaban) SmPC.pdf. Accessed December 27, 2011.
44. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170:1433-1441.
45. Oldgren J, Budaj A, Granger CB, et al. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J. 2011;32:2781-2789.
46. Boehinger Ingelheim Pharmaceuticals I. New Drug Application (NDA) 22-512: Dabigatran Etexilate. Available at: http://www.fda.gov/downloads/ advisorycommittees/ committeesmeetingmaterials/drugs/ cardiovascularandrenaldrugsadvisorycommittee/ ucm226009.pdf. Accessed December 27, 2011.
47. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med. 2010;363:1875-1876.
48. Uchino K, Hernandez AV. Dabigatran Association With Higher Risk of Acute Coronary Events: Meta-analysis of Noninferiority Randomized Controlled Trials. Arch Intern Med. 2012;172:397-402.